The Medical Letter on Drugs and Therapeutics
Naproxen/Esomeprazole (Vimovo)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the marketing of Vimovo (AstraZeneca), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) naproxen and the proton pump inhibitor (PPI) esomeprazole, for symptomatic relief of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk for NSAID-associated ulcers.

NSAIDS and GI TOXICITY — NSAIDs inhibit synthesis of prostaglandins, which have a protective effect on the gastric mucosa. Up to 40% of chronic NSAID users report having dyspepsia, and 1-2% develop life-threatening consequences of peptic ulcer disease such as hemorrhage and perforation.1 Three classes of medications have been shown to prevent endoscopically detected ulcers in NSAID users: the prostaglandin E1 analog misoprostol (Cytotec, and others), H2-blockers such as ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Naproxen Esomeprazole (Vimovo)
Article code: 1347b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian